[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100353008":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":37,"centralContacts":41,"locations":46,"responsibleParty":62,"collaborators":10,"id":65,"slug":10,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":10,"maxAge":10,"enrollmentInfo":72,"targetDuration":10,"studyType":75,"phases":10,"briefSummary":76,"conditions":77,"keywords":10,"overallStatus":48,"whyStopped":10,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"University of Louisville","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"People presenting with the Sx of Gp",null,"People presenting with the symptoms of gastroparesis. The three main interventions are GI neuromodulation, immunotherapy, and pyloric therapies.",[13,14,15],"Device: GI Neuromodulation","Drug: Immunotherapy","Procedure: Pyloric Therapies",[17,24,31],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"DEVICE","GI Neuromodulation","The investigators would include follow up with: No treatment; temp GES only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological\u002Fbehavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.",[9],[23],"Gastric electrical stimulation (GES)",{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","Immunotherapy","The investigators would include follow up with: No treatment; temp gastric electrical stimulation (GES) only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological\u002Fbehavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.",[9],[30],"Intravenous immunoglobulin",{"type":32,"name":33,"description":27,"armGroupLabels":34,"otherNames":35},"PROCEDURE","Pyloric Therapies",[9],[36],"Pyloromyotomy",[38],{"name":39,"affiliation":5,"role":40},"Thomas Abell, MD","PRINCIPAL_INVESTIGATOR",[42],{"name":39,"role":43,"phone":44,"phoneExt":10,"email":45},"CONTACT","(502)852-6991","thomas.abell@louisville.edu",[47],{"facility":5,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"RECRUITING","Louisville","Kentucky","40202","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-85.75941,38.25424,{"lat":58,"lon":57},[61],{"name":39,"role":43,"phone":10,"phoneExt":10,"email":10},{"type":40,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Thomas Abell","The Arthur M Schoen MD Chair in Gastroenterology","100353008",false,"NCT03876288","Gastroparesis Outcome Longitudinal Database Enrolled Numerically","GOLDEN","Inclusion:\n\n* Patients with the symptoms (Sx) of drug refractory gastroparesis\n* Disordered nutrition by standardized assessment\n* Ability to assess current symptom status\n* Ability to measure other medical conditions\n\nExclusion:\n\n* Anatomic obstruction of the GI Tract\n* Pregnancy\n* Inability of patient or guardian to sign informed consent, if needed\n* Psychiatric disorders precluding assessment and treatment of the patient's GI condition","ALL",{"count":73,"type":74},3000,"ESTIMATED","OBSERVATIONAL","GOLDEN is a longitudinal database of patients with the symptoms (Sx) of gastroparesis (Gp) who were seen and recorded at the University of Louisville from 2012 and is ongoing. Patients are enrolled and followed by sequential numbers and may include legacy patients seen at other centers by some of the same team and who are reported as part of the series. Outcome relate to patients Sx, survival, quality of life and other measures as detailed below, over time. The study tracks patients regardless of treatment but specifically focuses on GI Neuromodulation (gastric electrical stimulation - GES), Immunotherapy (IVIG), and Pyloric therapies (pyloroplasty, endoscopic). If treatments were administered GOLDEN allows for examination and stratification of outcome by groups both at baseline and at follow up.",[78],"Gastroparesis","2026-04-17",{"date":81,"type":82},"2026-04-20","ACTUAL",{"date":84,"type":82},"2013-01-01",{"date":86,"type":74},"2028-01-01",{"name":5,"class":6},1]